Group 1 - RSV is the leading pathogen for lower respiratory tract infections in infants globally, causing approximately 33 million cases, 3.6 million hospitalizations, and 101,400 deaths annually among children under five, with 97% of deaths occurring in low- and middle-income countries [1][2] - The innovative drug Ziresovir, developed by Shanghai Aike Baifa Biopharmaceutical Technology Co., Ltd., has been officially included in the WHO's PADO-RSV priority list, marking it as the first and only RSV antiviral treatment to be recognized on this list [1][3] - The WHO/GAP-f initiative aims to systematically review the global RSV research pipeline, clarify research priorities, and promote the development and accessibility of RSV prevention and treatment drugs suitable for children [2] Group 2 - Ziresovir is a novel small molecule inhibitor targeting the RSV fusion protein, preventing viral entry into human cells and blocking cell-to-cell fusion, which is characteristic of RSV infection [3] - The phase III clinical trial results for Ziresovir have been published in prestigious journals, making it the first targeted RSV antiviral drug to successfully complete phase III trials with positive outcomes, and it is the first children's innovative drug invented and developed in China for global expansion [3]